GeneQuine selects Exothera to support the next stage of its osteoarthritis gene therapy development

September 9th 2021


GeneQuine Biotherapeutics GmbH, a biotech company focused on the development of gene therapy for musculoskeletal disorders, today announced that it has contracted Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), to conduct a feasibility study for the development of a large-scale manufacturing process for its osteoarthritis gene therapy product candidate GQ- 303 in the highly scalable scale-X™ fixed-bed bioreactor.

Read Pdf